All Stories

  1. The within-person bidirectional association between physical activity and loneliness in the daily lives of adolescents and young adults
  2. De Belgische Euthanasiewet doorstaat de mensenrechtelijke toets, behalve voor de a posteriori-controle (Mortier tegen België (nr. 78017/17))
  3. Coping and sleep quality in youth: An Experience Sampling study
  4. Media coverage of Belgium’s first criminal case concerning euthanasia for psychiatric patients: A content analysis of Flemish newspapers and magazines
  5. New Directions in the Ethics of Assisted Suicide and Euthanasia
  6. The Belgian euthanasia law under scrutiny of the highest courts
  7. Prevalence and characteristics of registered falls in a Belgian University Psychiatric Hospital
  8. Klassieke psychedelica als behandeling voor depressie: waar staan we vandaag?
  9. The relationship between daily positive future thinking and past-week suicidal ideation in youth: An experience sampling study
  10. Falls Among Psychiatric Inpatients: A Systematic Review of Literature
  11. Improving control over euthanasia of persons with psychiatric illness: Lessons from the first Belgian criminal court case concerning euthanasia
  12. Correction to: 49th ESCP virtual symposium on clinical pharmacy 19.10.2021–21.10.2021 Clinical pharmacy, working collaboratively in mental health care
  13. Be(com)ing social: Daily-life social interactions and parental bonding.
  14. Barriers to Somatic Health Care for Persons With Severe Mental Illness in Belgium: A Qualitative Study of Patients' and Healthcare Professionals' Perspectives
  15. COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review
  16. Depression and post-traumatic stress disorder after perinatal loss in fathers: A systematic review
  17. Euthanasia of a person with a psychiatric disorder does not violate the European Convention on Human Rights (Mortier v. Belgium [no. 78017/17])
  18. COVID-19 Vaccination Rates in a Cohort Study of Patients With Mental Illness in Residential and Community Care
  19. Momentary Manifestations of Negative Symptoms as Predictors of Clinical Outcomes in People at High Risk for Psychosis: Experience Sampling Study
  20. COVID-19 vaccine uptake in patients with psychiatric disorders admitted to or residing in a university psychiatric hospital
  21. Emotion regulation in response to daily negative and positive events in youth: The role of event intensity and psychopathology
  22. Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study
  23. The Role of Working Memory in the Processing of Scalar Implicatures of Patients With Schizophrenia Spectrum and Other Psychotic Disorders
  24. COVID-19 vaccination for people with severe mental illness: why, what, and how?
  25. Network dynamics of momentary affect states and future course of psychopathology in adolescents
  26. Model-based PID-5 domain clusters and levels of impairment in self and interpersonal functioning
  27. The search for an autoimmune origin of psychotic disorders: Prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens
  28. The clinical characterization of the patient with primary psychosis aimed at personalization of management
  29. The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled Trials
  30. Stress reactivity as a putative mechanism linking childhood trauma with clinical outcomes in individuals at ultra-high-risk for psychosis: Findings from the EU-GEI High Risk Study
  31. Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital
  32. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study
  33. Risk of Hospitalized Falls and Hip Fractures in 22,103 Older Adults Receiving Mental Health Care vs 161,603 Controls: A Large Cohort Study
  34. Links between the amount of antipsychotic medication prescribed per population at general practice level, local demographic factors and medication selection
  35. Prioritizing COVID ‐19 vaccination for people with severe mental illness
  36. Early warning signals in psychopathology: what do they tell?
  37. Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness
  38. The clinical characterization of the adult patient with depression aimed at personalization of management
  39. General psychopathology and its social correlates in the daily lives of youth
  40. Lower emotional complexity as a prospective predictor of psychopathology in adolescents from the general population.
  41. Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study
  42. Polygenic liability for schizophrenia and childhood adversity influences daily‐life emotion dysregulation and psychosis proneness
  43. Measuring resilience prospectively as the speed of affect recovery in daily life: a complex systems perspective on mental health
  44. Test-retest reliability, concurrent validity and correlates of the two-minute walk test in outpatients with psychosis
  45. TwinssCan — Gene-Environment Interaction in Psychotic and Depressive Intermediate Phenotypes: Risk and Protective Factors in a General Population Twin Sample
  46. Barriers, attitudes, confidence, and knowledge of nurses regarding metabolic health screening and intervention in people with mental illness: a pilot study from Uganda
  47. Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study
  48. The sublingual use of atropine in the treatment of clozapine‐induced sialorrhea: A systematic review
  49. Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study
  50. Reduced interhemispheric and increased intrahemispheric connectivity in schizophrenia brain networks
  51. A quantitative assessment of the views of mental health professionals on exercise for people with mental illness: perspectives from a low-resource setting
  52. Evidence for interaction between genetic liability and childhood trauma in the development of psychotic symptoms
  53. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis
  54. 7.3 POLYGENIC RISK FOR SCHIZOPHRENIA MODERATES THE INFLUENCE OF CHILDHOOD ADVERSITY ON DAILY-LIFE EMOTIONAL DYSREGULATION AND PSYCHOSIS PRONENESS
  55. Associations of the Built Environment With Physical Activity and Sedentary Time in Ugandan Outpatients With Mental Health Problems
  56. Health care professionals’ perspectives on physical activity within the Ugandan mental health care system
  57. Evidence that the association of childhood trauma with psychosis and related psychopathology is not explained by gene-environment correlation: A monozygotic twin differences approach
  58. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
  59. Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder
  60. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study
  61. The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication
  62. Patients with psychosis struggle with scalar implicatures
  63. S182. Evidence That the Polygenic Risk Score for Neuroticism Does Not Moderate the Impact of Childhood Trauma on Neuroticism: A GxE Model
  64. O42. Gene-Environment Correlation Does not Explain Away the Association Between Childhood Trauma and Psychopathology: A Monozygotic Twin Differences Approach
  65. Exercise self-efficacy correlates in people with psychosis
  66. O4.4. DOES POLYGENIC RISK SCORE FOR SCHIZOPHRENIA MODERATE THE MOMENTARY AFFECTIVE AND PSYCHOTIC REACTIONS TO DAILY-LIFE STRESSORS?
  67. Sensitivity to Peer Evaluation and Its Genetic and Environmental Determinants: Findings from a Population-Based Twin Study
  68. Adherence to physical activity recommendations and physical and mental health risk in people with severe mental illness in Uganda
  69. Self-Reported Cognitive Biases Are Equally Present in Patients Diagnosed With Psychotic Versus Nonpsychotic Disorders
  70. Psychosis, Antipsychotic Medication, and Sexual Dysfunctions
  71. Validity and correlates of the International Physical Activity Questionnaire in first-episode psychosis
  72. Network Approach to Understanding Emotion Dynamics in Relation to Childhood Trauma and Genetic Liability to Psychopathology: Replication of a Prospective Experience Sampling Analysis
  73. The Bitter, Expensive Pill at the End of Life
  74. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis
  75. Is sensitivity to daily stress predictive of onset or persistence of psychopathology?
  76. White noise speech illusion and psychosis expression: An experimental investigation of psychosis liability
  77. Sedentary Behavior in People Living With HIV: A Systematic Review and Meta-Analysis
  78. Perceived Stress and Its Relationship With Chronic Medical Conditions and Multimorbidity Among 229,293 Community-Dwelling Adults in 44 Low- and Middle-Income Countries
  79. Psychological and Biological Validation of a Novel Digital Social Peer Evaluation Experiment (digi-SPEE)
  80. Physical activity correlates in people living with HIV/AIDS: a systematic review of 45 studies
  81. Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time
  82. The Relationship Between the Personality Inventory for the DSM-5 (PID-5) and the Psychotic Disorder in a Clinical Sample
  83. Reversing the downward spiral for people with severe mental illness through educational innovations
  84. A systematic review of physical activity policy recommendations and interventions for people with mental health problems in Sub-Saharan African countries
  85. Global physical activity levels among people living with HIV: a systematic review and meta-analysis
  86. The prevalence of diabetes mellitus type 2 in people with alcohol use disorders: a systematic review and large scale meta-analysis
  87. Dropout from physical activity interventions in people living with HIV: a systematic review and meta-analysis
  88. Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations
  89. Dropout from physical activity interventions in children and adolescents with attention deficit hyperactivity disorder: A systematic review and meta-analysis
  90. Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study
  91. Is autonomous motivation the key to maintaining an active lifestyle in first-episode psychosis?
  92. Physical activity and sedentary behavior in people with bipolar disorder: A systematic review and meta-analysis
  93. The Functional Exercise Capacity Is Associated With Global Functioning in People With Bipolar Disorder
  94. BMI independently relates to glycaemia in patients with severe enduring mental illness (SMI)
  95. Impact of antipsychotic medication on physical activity and physical fitness in adolescents: An exploratory study
  96. Sitting time, physical fitness impairments and metabolic abnormalities in people with bipolar disorder: An exploratory study
  97. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis
  98. Serious reportable events within the inpatient mental health care: Impact on physicians and nurses
  99. Cardiorespiratory fitness in outpatients with bipolar disorder versus matched controls: An exploratory study
  100. The Prevalence of Metabolic Syndrome in Alcohol Use Disorders: A Systematic Review and Meta-analysis
  101. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders
  102. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis
  103. The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis
  104. Depressive symptoms and muscular fitness contribute independently to the ability to perform daily life activities in people with bipolar disorder
  105. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review
  106. DSM-5 section III personality traits and section II personality disorders in a Flemish community sample
  107. Genetic Evaluation of Schizophrenia Using the Illumina HumanExome Chip
  108. Concurrent validity of the international physical activity questionnaire in outpatients with bipolar disorder: Comparison with the Sensewear Armband
  109. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics
  110. Physical activity as a vital sign in patients with schizophrenia: Evidence and clinical recommendations
  111. Knowledge of Psychiatric Nurses About the Potentially Lethal Side-Effects of Clozapine
  112. Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis
  113. Type 2 Diabetes Mellitus
  114. Structural Brain Connectivity as a Genetic Marker for Schizophrenia
  115. Attitudes of Psychiatric Nurses about the Request for Euthanasia on the Basis of Unbearable Mental Suffering(UMS)
  116. Reply
  117. Validity of the 6min walk test in outpatients with bipolar disorder
  118. Do Advanced Statistical Techniques Really Help in the Diagnosis of the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics?
  119. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
  120. The functional exercise capacity in patients with bipolar disorder versus healthy controls: A pilot study
  121. A Systematic Review of Physical Activity Correlates in Alcohol Use Disorders
  122. Test–retest reliability, feasibility and clinical correlates of the Eurofit test battery in people with bipolar disorder
  123. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics
  124. Health-related quality of life and aerobic fitness in people with schizophrenia
  125. Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
  126. Promotion of physical health in persons with schizophrenia: can we prevent cardiometabolic problems before they begin?
  127. Prevalence and Predictors of Type 2 Diabetes Mellitus in People With Bipolar Disorder
  128. Aerobic capacity is associated with global functioning in people with schizophrenia
  129. Absence ofN-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia
  130. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review
  131. TYPE 2 DIABETES IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS OF PREVALENCE ESTIMATES AND PREDICTORS
  132. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
  133. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
  134. Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
  135. Health-related physical fitness in patients with bipolar disorder vs. healthy controls: An exploratory study
  136. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview
  137. Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta-analysis
  138. The Construct Validity of the Dutch Personality Inventory for DSM-5 Personality Disorders (PID-5) in a Clinical Sample
  139. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis
  140. Associations Between Metabolic and Aerobic Fitness Parameters in Patients With Schizophrenia
  141. Negative symptoms are associated with lower autonomous motivation towards physical activity in people with schizophrenia
  142. Associative stigma in family members of psychotic patients in Flanders: An exploratory study
  143. A Clinical Review of the Treatment of Catatonia
  144. Metabolic syndrome and lung function in schizophrenia: A pilot study
  145. The prevalence and moderators of clinical pain in people with schizophrenia: A systematic review and large scale meta-analysis
  146. Single-subject classification of schizophrenia patients based on a combination of oddball and mismatch evoked potential paradigms
  147. Reliability and clinical correlates of the Astrand–Rhyming sub-maximal exercise test in patients with schizophrenia or schizoaffective disorder
  148. Treatment Continuation and Treatment Characteristics of 3 Long Acting Antipsychotic Medications (Paliperidone Palmitate, Risperidone Microspheres and Haloperidol Decanoate) in Belgium
  149. Somatic Problems and Dual Disorder Patients
  150. Analysis of auto-antibodies in schizophrenia
  151. C.11.01 Metabolic effects in schizophrenia: perception versus reality
  152. Changes in physical activity, physical fitness, self-perception and quality of life following a 6-month physical activity counseling and cognitive behavioral therapy program in outpatients with binge eating disorder
  153. Analysis of pathogenic autoantibodies against the N-methyl-d-aspartate glutamate receptor in schizophrenia
  154. Self-determination and stage of readiness to change physical activity behaviour in schizophrenia
  155. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis
  156. The functional exercise capacity and its correlates in obese treatment-seeking people with binge eating disorder: an exploratory study
  157. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia
  158. Variability in Working Memory Performance Explained by Epistasis vs Polygenic Scores in theZNF804APathway
  159. Severe mental illness: antipsychotics (revision number 8)
  160. In search of biomarkers for schizophrenia using electroencephalography
  161. Markers of inflammation in schizophrenia: association vs. causation
  162. Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations
  163. No association between genetic or epigenetic variation in insulin growth factors and antipsychotic-induced metabolic disturbances in a cross-sectional sample
  164. The Assessment, Benefits and Delivery of Physical Activity in People with Schizophrenia: A Survey of Members of the International Organization of Physical Therapists in Mental Health
  165. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review
  166. DYSGLYCEMIC SIGNALS IN CHILDREN AND ADOLESCENTS TREATED WITH ANTIPSYCHOTICS FOR THE FIRST TIME
  167. Poster #S175 THE ERYTHROCYTE MEMBRANE LIPID ABNORMALITIES OBSERVED IN SCHIZOPHRENIA PATIENTS SUPPORT THE OXIDATIVE STRESS HYPOTHESIS IN SCHIZOPHRENIA
  168. Poster #T176 THE INCREASED NUMBER OF PHOSPHOLIPID ABNORMALITIES OBSERVED IN THE ERYTHROCYTE MEMBRANE OF SCHIZOPHRENIA PATIENTS IS ASSOCIATED WITH INCREASED PSYCHOPATHOLOGY
  169. Health related quality of life, physical fitness and physical activity participation in treatment-seeking obese persons with and without binge eating disorder
  170. Registration of aggressive incidents in an adolescent forensic psychiatric unit and implications for further practice
  171. The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
  172. Associations between expiratory spirometry parameters and limitations in daily life activities in patients with schizophrenia
  173. Dysmetabolic features of the overweight patients receiving antipsychotic drugs: A comparison with normal weight and obese subjects
  174. The assessment of creativity in creativity/psychopathology research – a systematic review
  175. Diabetes Risk Potentially Underestimated in Youth and Children Receiving Antipsychotics
  176. Corrections
  177. EPA Guidance on Tobacco Dependence and Strategies for Smoking Cessation in People with Mental Illness
  178. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci
  179. Neurobiological effects of physical exercise in schizophrenia: a systematic review
  180. Creativity and Psychopathology: A Systematic Review
  181. Preliminary study of associative stigma among trainee psychiatrists in Flanders, Belgium
  182. Associations between perceived neighbourhood environmental attributes and self-reported sitting time in patients with schizophrenia: A pilot study
  183. Physical activity and sedentary behaviour in outpatients with schizophrenia: A systematic review and meta-analysis
  184. The importance of self-determined motivation towards physical activity in patients with schizophrenia
  185. The one and the many: effects of the cell adhesion molecule pathway on neuropsychological function in psychosis
  186. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables
  187. There is a need for physiotherapists in the multidisciplinary treatment of schizophrenia
  188. Stigmatization of schizophrenia in Flemish newspapers
  189. Associations between physical activity and the built environment in patients with schizophrenia: a multi-centre study
  190. P.1.j.025 Abnormal cognitive salience but not WCST scores are associated with poor outcome in patients with schizophrenia
  191. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls
  192. End-of-Life (Care) Perspectives and Expectations of Patients With Schizophrenia
  193. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
  194. Physical Activity Correlates in Persons with Binge Eating Disorder: A Systematic Review
  195. Antipsychotics for acute schizophrenia: making choices
  196. Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: A meta-analysis
  197. Diabetes, physical activity participation and exercise capacity in patients with schizophrenia
  198. Response to Bartoli et al.
  199. A systematic review of physical therapy interventions for patients with anorexia and bulemia nervosa
  200. The Cognitive Biases Questionnaire for Psychosis (CBQ-P) and the Davos Assessment of Cognitive Biases (DACOBS): Validation in a Flemish sample of psychotic patients and healthy controls
  201. Frequency, Characteristics and Management of Adolescent Inpatient Aggression
  202. Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine
  203. Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia
  204. All SNPs Are Not Created Equal: Genome-Wide Association Studies Reveal a Consistent Pattern of Enrichment among Functionally Annotated SNPs
  205. Screening for diabetes in severe mental illness (revision number 16)
  206. A systematic review on physical therapy interventions for patients with binge eating disorder
  207. CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia
  208. SOCIAL ANXIETY IN PHYSICAL ACTIVITY PARTICIPATION IN PATIENTS WITH MENTAL ILLNESS: A CROSS-SECTIONAL MULTICENTER STUDY
  209. Genetic Schizophrenia Risk Variants Jointly Modulate Total Brain and White Matter Volume
  210. Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs
  211. Schizophrenia genetic variants are not associated with intelligence
  212. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
  213. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone
  214. Genome-Wide Association Study of Clinical Dimensions of Schizophrenia: Polygenic Effect on Disorganized Symptoms
  215. Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia
  216. Common variant at 16p11.2 conferring risk of psychosis
  217. Replication Study and Meta-Analysis in European Samples Supports Association of the 3p21.1 Locus with Bipolar Disorder
  218. Creativity and Psychiatric Illness: The Search for a Missing Link - An Historical Context for Current Research
  219. Genetic Variation Underlying Psychosis-inducing Effects of Cannabis: Critical Review and Future Directions
  220. Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder
  221. Osteoporosis and fracture risk in people with schizophrenia
  222. Eurofit test battery in patients with schizophrenia or schizoaffective disorder: Reliability and clinical correlates
  223. Authors' reply
  224. Medical outcome of psychiatric inpatients with admission hyponatremia
  225. Safety and tolerability of antipsychotic polypharmacy
  226. Yoga in schizophrenia: a systematic review of randomised controlled trials
  227. SYSTEMATIC EVALUATION OF GUIDELINES FOR MONITORING CARDIO-METABOLIC RISK IN SCHIZOPHRENIA
  228. INTERNATIONAL ORGANIZATION OF PHYSICAL THERAPY IN MENTAL HEALTH-CONSENSUS ON PHYSICAL ACTIVITY WITHIN MULTIDISCIPLINARY REHABILITATION PROGRAMMES FOR MINIMISING CARDIO-METABOLIC RISK IN PATIENTS WITH SCHIZOPHRENIA
  229. Poster #99 CNR1 AND RISK OF THE METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA
  230. Poster #81 GENETIC VARIATION IN ABCB1 ASSOCIATED WITH P300 AMPLITUDE IN SCHIZOPHRENIA
  231. Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genes
  232. Parsing the components of the psychomotor syndrome in schizophrenia
  233. The functional exercise capacity is correlated with global functioning in patients with schizophrenia
  234. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study
  235. Prediabetes in Patients Treated With Antipsychotic Drugs
  236. A systematic review of correlates of physical activity in patients with schizophrenia
  237. Metaphor interpretation and use: A window into semantics in schizophrenia
  238. Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data
  239. Systematic Review of the Benefits of Physical Therapy Within a Multidisciplinary Care Approach for People With Schizophrenia
  240. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: Evidence for a common genetic vulnerability?
  241. The METEOR study
  242. International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia
  243. Genome-wide association study identifies five new schizophrenia loci
  244. Endogenic and Iatrogenic Diabetes Mellitus in Drug-naïve Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment Algorithm
  245. P.2.e.023 Long -term metabolic effects of aripiprazole adjunctive to lithium, valproate or lamotrigine
  246. Association of the metabolic syndrome with physical activity performance in patients with schizophrenia
  247. C.03.03 Improving patient outcomes: optimising efficacy and safety of antipsychotic treatment
  248. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices
  249. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation
  250. Common variants at VRK2 and TCF4 conferring risk of schizophrenia
  251. Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe
  252. Lack of physical activity during leisure time contributes to an impaired health related quality of life in patients with schizophrenia
  253. Knowledge about HIV in People with Schizophrenia: A General Population Comparison
  254. Efectos adversos metabólicos y endocrinos de los antipsicóticos de segunda generación en niños y adolescentes: una revisión sistemática de ensayos aleatorizados, controlados con placebo y guías de práctica clínica
  255. Smoking cessation for patients on clozapine
  256. Dual association of a TRKA polymorphism with schizophrenia
  257. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
  258. Reliability, minimal detectable changes, practice effects and correlates of the 6-min walk test in patients with schizophrenia
  259. Physical activity participation, functional exercise capacity and self-esteem in patients with schizophrenia
  260. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
  261. Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza
  262. Effects of progressive muscle relaxation on state anxiety and subjective well-being in people with schizophrenia: a randomized controlled trial
  263. Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study
  264. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder
  265. Age at onset of psychotic disorder: Cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction
  266. Prevalence and correlates of seclusion and restraint use in children and adolescents: a systematic review
  267. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs
  268. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
  269. Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia
  270. Second-generation antipsychotics and constipation: A review of the literature
  271. A head-to-head comparison of sertindole and risperidone on metabolic parameters
  272. WITHDRAWN: Maladie cardiovasculaire et diabète chez les sujets souffrant d’une maladie mentale sévère. Déclaration de position de l’European Psychiatric Association (EPA), soutenue par l’European Association for the Study of Diabetes (EASD) et l’Europe...
  273. Editorial for Nordic Journal of Psychiatry
  274. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone
  275. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study
  276. State anxiety, psychological stress and positive well-being responses to yoga and aerobic exercise in people with schizophrenia: a pilot study
  277. MTHFR and risk of metabolic syndrome in patients with schizophrenia
  278. No association between MTHFR C677T or A1298C and age at onset of schizophrenia
  279. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia
  280. Management of physical health in patients with schizophrenia: practical recommendations
  281. Physical health management in psychiatric settings
  282. Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia
  283. MTHFR GENOTYPE AND DIFFERENTIAL EVOLUTION OF METABOLIC PARAMETERS AFTER INITIATION OF A SECOND GENERATION ANTIPSYCHOTIC
  284. VRINT: A NEWLY DEVELOPED EARLY PSYCHOSIS SERVICE IN BELGIUM
  285. AGE AT ONSET OF PSYCHOSIS IN PATIENTS WITH SCHIZOPHRENIA: EVIDENCE FOR A SEX-DEPENDENT INTERACTION BETWEEN BDNF VAL66MET GENOTYPE AND CANNABIS USE
  286. DO ANTIPSYCHOTIC MEDICATIONS REDUCE OR INCREASE MORTALITY IN SCHIZOPHRENIA? A CRITICAL APPRAISAL OF THE FIN-11 STUDY
  287. IN VIVO PET IMAGING OF CEREBRAL TYPE 1 CANNABINOID RECEPTOR AVAILABILITY IN PATIENTS WITH SCHIZOPHRENIA
  288. PREVALENCE AND SEVERITY OF ANTIPSYCHOTIC RELATED CONSTIPATION
  289. METABOLIC PARAMETERS IN A SUBSET OF PATIENTS IN THE SCOP STUDY
  290. O78 Effets contrastés de l’olanzapine et de la rispéridone sur les taux plasmatiques d’adiponectine chez les patients schizophrènes nouvellement traités
  291. Maladie cardiovasculaire et diabète chez les personnes atteintes d’une maladie mentale sévère
  292. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study
  293. Antipsychotic Use and Risk for Hyperglycemia in Elderly Patients With DM
  294. Cardiometabolic effects of physical activity interventions for people with schizophrenia
  295. Evaluation of the association between insight and symptoms in a large sample of patients with schizophrenia
  296. Mortality in patients with schizophrenia
  297. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (...
  298. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia
  299. Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?
  300. Advantages and disadvantages of combination treatment with antipsychotics
  301. The relation between neurocognitive dysfunction and impaired insight in patients with schizophrenia
  302. Prevalence of HIV and hepatitis C infection among patients with schizophrenia
  303. Metabolic syndrome in people with schizophrenia: a review
  304. Cardiovascular disease and diabetes in people with severe mental illness
  305. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder
  306. Traitements neuroleptiques et troubles métaboliques
  307. Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances
  308. P.3.c.070 Metabolic disorders in patients with schizophrenia treated by antipsychotic drugs in Europe: the METEOR study
  309. P.3.c.071 Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study
  310. A roadmap to disentangle the molecular etiology of schizophrenia
  311. Incidence of schizophrenia lower in people with type I diabetes
  312. Comorbid Somatic Illnesses in Patients With Severe Mental Disorders
  313. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
  314. Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder
  315. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
  316. Evidence that the COMTVal158Met polymorphism moderates sensitivity to stress in psychosis: An experience-sampling study
  317. C.21.03 Management strategies for patients with a present or emerging health risk
  318. P.2.f.005 Membrane phospholipid distribution: a comparison between patient with schizophrenia and bipolar disorder
  319. The association between cognition and functional outcome in first-episode patients with schizophrenia: mystery resolved?
  320. Anticholinergic use in hospitalised schizophrenic patients in Belgium
  321. Abnormal glucose metabolism in patients treated with antipsychotics
  322. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine
  323. Remission criteria for schizophrenia: Evaluation in a large naturalistic cohort
  324. A Case Series: Evaluation of the Metabolic Safety of Aripiprazole
  325. Impact of antipsychotic treatment on physical health
  326. Preliminary results of the Belgian lifestyle program ENERGIE on weight in patients with psychiatric disorders
  327. Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder
  328. Premorbid IQ as a predictor for the course of IQ in first onset patients with schizophrenia: A 10-year follow-up study
  329. Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE®
  330. Letter to the Editor
  331. Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder
  332. Reversibility of Antipsychotic Treatment–Related Diabetes in Patients With Schizophrenia
  333. The five-factor model of the Positive and Negative Syndrome Scale I: Confirmatory factor analysis fails to confirm 25 published five-factor solutions
  334. The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model
  335. Usefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia
  336. Stereotypy in schizophrenia
  337. Oral glucose tolerance tests in treated patients with schizophrenia.
  338. Schizophrenia: who is at risk? Who is a case?
  339. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
  340. P.3.d.003 A cross-sectional study of adiponectin in patients with schizophrenia
  341. P.3.c.005 Evaluation of the metabolic safety of aripiprazole
  342. P.3.c.004 Screening for metabolic abnormalities in patients with schizophrenia treated with antipsychotics: are we doing enough?
  343. Pharmacological treatment of hospitalised schizophrenic patients in Belgium
  344. GLUCOSE ABNORMALITIES IN A NON-PSYCHOTIC PATIENT TREATED WITH RISPERIDONE
  345. Belgian consensus on metabolic problems associated with atypical antipsychotics
  346. PMH45 MAPPING UTILITY SCORES FROM THE EQ-5D AND SF-6D ONTO THE SCHIZOPHRENIA QUALITY OF LIFE SCALE
  347. Expressed Emotion in the Client-Professional Dyad
  348. The Generic Alternative in Schizophrenia
  349. Psychotic disorders in Prader-Willi syndrome
  350. Safe ECT in a Patient With the Ehlers–Danlos Syndrome
  351. P.2.056 Sound and vision, using popular media to improve knowledge about schizophrenia
  352. P.2.054 Adherence to antipsychotic dosing guidelines in the treatment of hospitalised psychotic patients in Belgium
  353. P.2.055 The influence of antipsychotic drug treatment on anticholinergic use and complexity of medication schemes in hospitalised pschotic patient in Belgium
  354. Guidelines adherence in treated schizophrenic patients
  355. Expressed emotion in the client-professional caregiver dyad: are symptoms, coping strategies and personality related?
  356. Expressed emotion in staff-patient relationships: the professionals' and residents' perspectives
  357. The Care Perception Questionnaire
  358. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study
  359. Can we identify the factors influencing the burden on family members of patients with schizophrenia?
  360. Hospitalised schizophrenic patients in Belgium, demographic and clinical data
  361. Interscale validity of PECC, a psychosis evaluation tool for common use by caregivers
  362. Failure to establish linkage on the X chromosome in 301 families with schizophrenia or schizoaffective disorder
  363. Animal models of schizophrenia
  364. A 1-Year Cost-Effectiveness Model for the Treatment of Chronic Schizophrenia with Acute Exacerbations in Belgium
  365. Trail making data in schizophrenic patients
  366. Expressed emotion of professional caregivers of patients with schizophrenia. An exploration of the field
  367. Family stigma: A study of relatives of schizophrenic patients
  368. Intelligence data in first episode psychotic patients 10 years after hospital discharge
  369. Knowledge about schizophrenia in basic caregivers in Belgium
  370. Life chart data in first episode psychotic patients 10 years after hospital discharge
  371. Medication use in hospitalised schizophrenic patients in Belgium
  372. A genome-wide search for schizophrenia susceptibility genes
  373. Sexual dysfunction: The unspoken side effect of antipsychotics
  374. First-episode schizophrenia, a naturalistic 10 year follow-up study
  375. Introduction of clozapine in Belgium
  376. Health Care Expenditure on Schizophrenia Patients in Belgium
  377. High prevalence of Helicobacter pylori in institutionalized schizophrenic patients
  378. Rehabilitation and Resocialization for the Long-Term Mentally III in Belgium: Description of Services and History of Their Development
  379. High prevalence of helicobacfer pylori in schizophrenic patients
  380. No evidence for more auto-immune pathology in first degree relatives of schizophrenic patients
  381. PQCSPI, an instrument to measure the perception of quality of care for psychotic inpatients
  382. Suicide in Young Schizophrenic Patients During and After Inpatient Treatment
  383. Partial hospitalization at night: the Brussels Nighthospital
  384. Lujan-Fryns syndrome in the differential diagnosis of schizophrenia
  385. Psychotherapy with “New Chronic” Psychotic Patients
  386. The Brussels Night Hospital: A Three-year Follow-up Study
  387. Development of an instrument to measure consumers perception of quality of care for psychotic inpatients
  388. Study of the possible association of HLA class II, CD4, and CD3 polymorphisms with schizophrenia
  389. Treatment of the neuroleptic malignant syndrome with ECT
  390. The function of the brussels night hospital: Dumping, recycling or container?
  391. Management of lethal catatonia with dantrolene sodium
  392. Psychiatric Aspects of Suicidal Behaviour: Schizophrenia